Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by palinc2000on Nov 18, 2021 12:52pm
70 Views
Post# 34141519

RE:RE:Small deal for Cardiff in oncology with PFE

RE:RE:Small deal for Cardiff in oncology with PFE I like the fact that Cardiff was able to negotiate a stock issue to PFE at 19% above yesterdays Closing price and apparently PFE and PFE will see data 2 days before its released.Very smart  deal presumably negotiated by the recently hired new CFO....

SPCEO1 wrote: It is worth noting that the investment comes via the Pfizer Breakthrough Growth initiative and that Pfizer has been given the right to see data from their research before anyone else sees it. 

Could TH be on the receiving end of such an investment in the not too distant future. TH sure seems to fit the description of what Pfizer might be looking for in this program of theirs. And, we know that TH has the best possible connections already with Pfizer.

I ahve been wondering why TH has not yet updated the coroprate presentation on their website, which dates back to 7/19. Plenty has happened since then to justify an update but none has come. Perhaps this was just something they don't have time to get to due to Leah's departure. But maybe it also reflects the possibility that something meaningful is going to happen soon, such as a Pfizer investment like the one in Cardiff, and they f igure there is no reason to update it now when it will soon have to be updated again.

palinc2000 wrote: Cardiff shares up 15% 

https://seekingalpha.com/pr/18568137-cardiff-oncology-announces-15-million-equity-investment-from-pfizer-through-pfizer




<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse